Roche (RHHBY), the Breast International Group, Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, announced statistically significant final overall survival results from the phase III APHINITY study in people with HER2-positive early-stage breast cancer. After ten years, the risk of death was reduced by 17% for people treated with Perjeta, Herceptin and chemotherapy for a year as post-surgery treatment, compared with individuals who received Herceptin, chemotherapy, and placebo. A 21% reduction in the risk of death was seen in the prespecified subgroup of people with lymph node-positive disease.
The company noted that full results will be presented as a late-breaking abstract on 15 May at the 2025 European Society for Medical Oncology Breast Cancer Congress.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.